Euro-EWING99 long-term analysis defines outcomes in 3,395 patients with Ewing sarcoma
Five-year progression-free and overall survival were 55.4% and 64.6%, with metastatic status and histologic response remaining major prognostic factors.
Tag
High relevance
Escalating esophageal chemoradiotherapy from 50.4 to 60 Gy provided no benefit
Three-year outcomes numerically favored 50.4 Gy over 60 Gy, while multivariable analysis found no significant survival advantage from either dose.
Re-irradiation was associated with longer survival after pediatric diffuse midline glioma progression
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
Omitted guideline-recommended sectors drove local failure after sacral SBRT
Seventy-three percent of failures after nonadherent sacral contouring involved sectors that guidelines recommended including in the clinical target volume.
Pelvic insufficiency fractures affected nearly one-third after gynecologic IMRT
Pelvic insufficiency fractures occurred in 29.2% of patients, with postmenopause and elevated baseline t-PINP independently predicting risk.
Earlier lung cancer diagnosis exposed major delays in curative radiotherapy access
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.
Children’s Oncology Group guidelines standardize pediatric radiotherapy simulation across treatment sites and techniques
COG guidelines standardize pediatric radiotherapy simulation across treatment sites and techniques
Concurrent olaparib increased severe dermatitis during radiotherapy for inflammatory breast cancer
Adding low-dose olaparib increased grade 3 dermatitis from 5.5% to 24.7% during postmastectomy radiotherapy for inflammatory breast cancer.
Short-course total neoadjuvant therapy improved five-year survival in STELLAR
Five-year overall survival was 78.1% with short-course total neoadjuvant therapy versus 69.7% with long-course chemoradiotherapy.
Three-week locoregional breast radiotherapy was noninferior for arm lymphedema
40 Gy in 15 fractions did not increase three-year arm lymphedema or compromise recurrence and mortality outcomes compared with 50 Gy.
Oxaliplatin-based total neoadjuvant therapy improved three-year DFS in high-risk rectal cancer
Doublet total neoadjuvant therapy improved three-year disease-free survival, metastasis-free survival, and pathological complete response compared with conventional chemoradiotherapy.
ESTRO defined minimum standards for prostate SBRT implementation
ESTRO recommends prostate SBRT for selected intermediate-risk disease with MRI-based contouring, rigorous quality assurance, and daily image guidance.
Immune-sparing lung SBRT planning reduced lymphocyte loss in a randomized phase II trial
Optimizing dose to blood- and immune-rich structures reduced lymphocyte depletion and prevented grade 3 lymphopenia after early-stage lung SBRT.
RadComp protons lowered mean cardiac dose without improving early cardiac-related quality of life
Protons substantially reduced mean cardiac exposure, but no cardiac dose metric predicted patient-reported symptoms during the first six months.
Most PLATO quality-of-life deficits recovered by six months, but advanced disease remained burdensome
Most treatment-related deficits improved by six months, although bowel and sexual problems persisted in several standard-dose and locally advanced groups.